![]() |
Nestlé Health Science expands distribution of hemp products formulated with VESIsorb® into Europe under industry-leading brand, Pure Encapsulations® | ![]() |
Friday, 11. September 2020 14:45 |
---|
FORT COLLINS, Colo., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Geocann and Nestlé Health Science are proud to announce the European launch of CBD (from broad spectrum hemp extract) soft gel formulations utilizing the patented VESIsorb® drug delivery system for dramatically improved absorption and bioavailability. The first large-scale production was completed and delivered earlier this month using only European resources, from the cultivation and extraction of the hemp biomass in Slovenia to the drug delivery technology and soft gel capsule production in Switzerland. “We are extremely proud to expand our relationship with Nestlé’s healthcare professional brands into Europe after their success in the U.S. market this past year,” said Jesse Lopez, CEO and founder of Geocann. “Their leadership team’s validation of science-backed and clinically-proven hemp products is an important milestone for our industry and provides exceptional credibility to the therapeutic benefits of cannabinoids formulated with VESIsorb®.” VESIsorb® is a naturally self-assembling colloidal droplet delivery system that has been well-recognized as the industry leader for improving the bioavailability of poorly absorbed natural ingredients, like cannabinoids and terpenes, as proven in both well-designed pilot and peer-reviewed published studies. Most recently, the peer-reviewed journal, Molecules, published the results of a double-blind, cross-over design study comparing the pharmacokinetic (PK) parameters of a broad spectrum hemp extract formulated with VESIsorb® to that of the same broad spectrum hemp extract combined with medium chain triglyceride (MCT) oil. Overall, the VESIsorb® formulation showed statistically significant improvements for all measured pharmacokinetic parameters, including maximal plasma CBD concentration (Cmax), area under the curve (AUC), and time to peak absorption (Tmax). The complete manuscript can be accessed on Geocann’s website. “Together with Geocann, we share a passion and commitment to product safety, purity, and performance,” said Dr. Barry Ritz, Chief Science Officer at Pure Encapsulations. “Our partnership is built on a relentless effort to ensure these are the most science-backed CBD products in the world, setting the benchmark for what consumers expect and healthcare professionals demand.” Geocann is well-recognized for its substantial investments in research in order to meet the evolving demands of the hemp marketplace. According to Lopez, in addition to recent PK studies and the stability data for its products, further investments in new clinical research focused on both PK performance and clinical end points are well under way. Additionally, multiple toxicology studies have been completed and will be published this year as part of the company’s FDA GRAS (Generally Regarded As Safe) Notification and Novel Food application. About Geocann About Nestlé Health Science About Pure Encapsulations For more information and interview requests, please contact Sam Davidson at 970-657-2479 or sam@geocann.com. Contact: Sam Davidson A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e4314579-4cab-4087-ad3a-21897d257a24 CBD Soft Gels Powered By VESIsorbGeocann has the exclusive global rights to the patented VESIsorb® drug delivery technology for cannabinoids, terpenes, and flavonoid formulations. The technology has been successfully applied to a wide range of cannabis based product applications, including soft gel and hard shell capsules, functional foods (e.g. gummies) and beverages, powder systems, tinctures, sublingual sprays, and topically applied formulations. |
Related Links: |
Author: Copyright GlobeNewswire, Inc. 2016. All rights reserved. You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account. |